Department of Hand Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Department of Orthopaedics and Traumatology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
In Vivo. 2022 May-Jun;36(3):1267-1273. doi: 10.21873/invivo.12826.
Background/Aim Enchondroma is the most common primary bone tumour of the hand. When surgery is indicated, curettage with or without void augmentation has been described. However, only few comparative studies exist. The aim of this study was to compare the outcomes of hand enchondromas treated with autologous bone graft (AG) and bioactive glass S53P4 (BAG).
A retrospective comparative analysis was conducted among patients surgically treated for hand enchondromas at a tertiary referral centre during a 17-year period.
A total of 190 patients (116 AG vs. 74 BAG) with 205 enchondromas were included. No statistically significant differences in outcome measures were observed. A reoperation was performed in five patients in the autologous bone-graft group; one patient presented a rare malignant transformation from enchondroma to chondrosarcoma after the primary operation. No reoperations were performed in the BAG group.
Although AG is the gold standard for filling bony cavities, bone-graft retrieval can cause complications and postoperative pain. Our results suggest that S53P4 BAG is a safe and effective bone-graft material alternative for filling of enchondroma-evacuated cavities.
背景/目的：内生软骨瘤是手部最常见的原发性骨肿瘤。当需要手术时，已描述了刮除术联合或不联合骨腔填充的治疗方法。然而，仅有少数比较性研究存在。本研究旨在比较自体骨移植物（AG）和生物活性玻璃 S53P4（BAG）治疗手部内生软骨瘤的疗效。
在 17 年期间，对在三级转诊中心接受手部内生软骨瘤手术治疗的患者进行了回顾性比较分析。
共纳入 190 例患者（116 例 AG 与 74 例 BAG），共 205 个内生软骨瘤。在结局评估方面，两组之间未观察到统计学上的显著差异。在自体骨移植物组中，有 5 例患者需要再次手术；1 例患者在初次手术后发生了罕见的内生软骨瘤恶变软骨肉瘤。BAG 组无再次手术病例。
尽管 AG 是填充骨腔的金标准，但取骨会导致并发症和术后疼痛。我们的结果表明，S53P4 BAG 是一种安全有效的替代自体骨移植物材料，可用于填充内生软骨瘤切除后的骨腔。
